Budesonide-formoterol reliever therapy in intermittent versus mild persistent asthma

Eur Respir J. 2021 Feb 17;57(2):2003064. doi: 10.1183/13993003.03064-2020. Print 2021 Feb.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Anti-Asthmatic Agents* / therapeutic use
  • Asthma* / drug therapy
  • Bronchodilator Agents / therapeutic use
  • Budesonide / therapeutic use
  • Drug Combinations
  • Ethanolamines
  • Formoterol Fumarate / therapeutic use
  • Humans

Substances

  • Anti-Asthmatic Agents
  • Bronchodilator Agents
  • Drug Combinations
  • Ethanolamines
  • Budesonide
  • Formoterol Fumarate

Associated data

  • ANZCTR/ACTRN12615000999538